GeoVax sees cash and credit lasting into December 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
GeoVax Labs, Inc. (GOVX) reported no government-contract revenue for the nine months ended September 30, 2026, versus $2,489,145 a year earlier, and a net loss of $13,844,500 versus $17,046,348. Research and development expense was $9,833,652, compared with $15,127,090. GeoVax attributed the lower expense mainly to the BARDA contract termination and lower GEO-CM04S1 trial and Gedeptin manufacturing costs, partly offset by higher GEO-MVA manufacturing costs. Cash used in operations was $11,536,528; cash and equivalents totaled $2,150,946 at September 30.
GeoVax said it believes existing cash and credit access are sufficient to fund operations into December 2026, but its plans do not fully alleviate substantial doubt about its ability to continue as a going concern. The October 25, 2026 revolving agreement permits loan requests before its first anniversary, up to $1,000,000 outstanding at 12% annual interest. Nasdaq staff determined to delist the stock after 30 consecutive business days below the $1.00 minimum bid; the hearing request stayed further action, and the hearing was held October 13, 2026. GeoVax said its stock traded near Nasdaq’s new $5 million minimum market value of listed securities. It effected a one-for-24 reverse split on November 11, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss was $13,844,500, versus $17,046,348 in 2025.
Negative
- Major pointNine-month government-contract revenue was $0, versus $2,489,145 in 2025.
- Major pointGoing-concern doubt remains despite stated funding sufficiency into December 2026.
- Major pointNasdaq staff's delisting determination followed 30 business days below the $1.00 minimum.
- Minor pointGeoVax said its stock traded near Nasdaq’s new $5 million minimum market-value threshold.
Filing Explained
GeoVax reports 606,230 potentially dilutive securities and an immediate-delisting rule if market value stays below $5 million for 30 trading days.
GeoVax’s quarterly report lists 606,230 potentially dilutive securities at
The filing says GeoVax’s stock trades near Nasdaq’s
Key Figures
Key Terms
substantial doubt financial
right-of-use assets financial
Warrant Exercise Inducement financial
antidilutive financial
Modified Vaccinia Ankara (MVA) medical
oncolytic solid tumor gene-directed therapy medical
Stock Split
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue and what net loss did GOVX report for the first nine months of 2026?
Why did Nasdaq issue a delisting determination for GOVX?
What are the terms of GeoVax’s revolving loan agreement?
When are GOVX’s GEO-MVA and Gedeptin trials planned?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (IRS Employer Identification No.) | |
| of incorporation or organization) |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each Class |
Trading Symbol |
Name of each Exchange on which Registered |
|
|
|
The Nasdaq Capital Market |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Emerging growth company | ||
| Smaller reporting company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
Yes
As of November 12, 2026,
TABLE OF CONTENTS
| Page | ||
| PART I – FINANCIAL INFORMATION | ||
| Item 1 | Condensed Consolidated Financial Statements: | |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 | 1 | |
| Condensed Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2026 and 2025 (unaudited) | 2 | |
| Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three-month and nine-month periods ended September 30, 2026 and 2025 (unaudited) | 3 | |
| Condensed Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2026 and 2025 (unaudited) | 4 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 5 | |
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 11 |
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 17 |
| Item 4 | Controls and Procedures | 17 |
| PART II – OTHER INFORMATION | ||
| Item 1 | Legal Proceedings | 18 |
| Item 1A | Risk Factors | 18 |
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 18 |
| Item 3 | Defaults Upon Senior Securities | 19 |
| Item 4 | Mine Safety Disclosures | 19 |
| Item 5 | Other Information | 19 |
| Item 6 | Exhibits | 20 |
| SIGNATURES | 21 | |
Part I -- FINANCIAL INFORMATION
Item 1 Financial Statements
GEOVAX LABS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|
September 30, |
December 31, |
|||||||
|
2026 |
2025 |
|||||||
|
(unaudited) |
||||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Prepaid expenses and other current assets |
||||||||
|
Total current assets |
||||||||
|
Property and equipment, net |
||||||||
|
Operating lease right-of-use assets |
||||||||
|
Other assets |
||||||||
|
Total assets |
$ | $ | ||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | $ | ||||||
|
Accrued expenses |
||||||||
|
Operating lease liability, current portion |
||||||||
|
Total current liabilities |
||||||||
|
Operating lease liability, net of current portion |
||||||||
|
Total liabilities |
||||||||
|
Commitments (Note 4) |
|
|
||||||
|
Stockholders’ equity: |
||||||||
|
Common stock, $.001 par value: |
||||||||
|
Authorized shares – |
||||||||
|
Additional paid-in capital |
||||||||
|
Accumulated deficit |
( |
) | ( |
) | ||||
|
Total stockholders’ equity |
||||||||
|
Total liabilities and stockholders’ equity |
$ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
GEOVAX LABS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Revenue from government contract |
$ | $ | $ | $ | ||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Research and development |
||||||||||||||||
|
General and administrative |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Loss from operations |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Other income |
||||||||||||||||
|
Interest income |
||||||||||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Basic and diluted: |
||||||||||||||||
|
Net loss per common share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Weighted average shares outstanding |
||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
GEOVAX LABS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)
|
Three-Month and Nine-Month Periods Ended September 30, 2026 |
||||||||||||||||||||
|
Total |
||||||||||||||||||||
|
Common Stock |
Additional |
Accumulated |
Stockholders’ |
|||||||||||||||||
|
Shares |
Amount |
Paid-in Capital |
Deficit |
Equity |
||||||||||||||||
|
Balance at December 31, 2025 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
|
Sale of common stock and warrants for cash |
||||||||||||||||||||
|
Issuance of common stock upon warrant exercises |
||||||||||||||||||||
|
Fractional share roundup following reverse split |
( |
) | ||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended March 31, 2026 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at March 31, 2026 |
( |
) | ||||||||||||||||||
|
Sale of common stock and warrants for cash |
||||||||||||||||||||
|
Issuance of common stock upon warrant exercises |
||||||||||||||||||||
|
Issuance of common stock for services |
||||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended June 30, 2026 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at June 30, 2026 |
( |
) | ||||||||||||||||||
|
Issuance of common stock upon warrant exercises |
||||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended September 30, 2026 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at September 30, 2026 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
|
Three-Month and Nine-Month Periods Ended September 30, 2025 |
||||||||||||||||||||
|
Total |
||||||||||||||||||||
|
Common Stock |
Additional |
Accumulated |
Stockholders’ |
|||||||||||||||||
|
Shares |
Amount |
Paid-in Capital |
Deficit |
Equity |
||||||||||||||||
|
Balance at December 31, 2024 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
|
Sale of common stock and warrants for cash |
||||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended March 31, 2025 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at March 31, 2025 |
( |
) | ||||||||||||||||||
|
Issuance of common stock upon warrant exercises |
||||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended June 30, 2025 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at June 30, 2025 |
( |
) | ||||||||||||||||||
|
Sales of common stock and warrants for cash |
||||||||||||||||||||
|
Issuance of common stock upon warrant exercises |
||||||||||||||||||||
|
Stock option expense |
- | |||||||||||||||||||
|
Net loss for the three months ended September 30, 2025 |
- | ( |
) | ( |
) | |||||||||||||||
|
Balance at September 30, 2025 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
See accompanying notes to condensed consolidated financial statements.
GEOVAX LABS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
Nine Months Ended September 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Cash flows from operating activities: |
||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Depreciation expense |
||||||||
|
Stock-based compensation expense |
||||||||
|
Loss on equipment sale and disposition |
||||||||
|
Changes in assets and liabilities: |
||||||||
|
Government contract receivable |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Other assets |
( |
) | ||||||
|
Accounts payable and accrued expenses |
( |
) | ||||||
|
Total adjustments |
||||||||
|
Net cash used in operating activities |
( |
) | ( |
) | ||||
|
Cash flows from investing activities: |
||||||||
|
Purchase of equipment |
( |
) | ||||||
|
Proceeds from sale of equipment |
||||||||
|
Net cash provided by (used in) investing activities |
( |
) | ||||||
|
Cash flows from financing activities: |
||||||||
|
Net proceeds from sale of common stock and warrants |
||||||||
|
Net proceeds from warrant exercises |
||||||||
|
Net cash provided by financing activities |
||||||||
|
Net increase (decrease) in cash and cash equivalents |
( |
) | ( |
) | ||||
|
Cash and cash equivalents at beginning of period |
||||||||
|
Cash and cash equivalents at end of period |
$ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
GEOVAX LABS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(unaudited)
1. Nature of Business
GeoVax Labs, Inc. (“GeoVax”, “us”, “we” or the “Company”) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
The Company’s primary development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. The program is advancing under an expedited regulatory pathway in Europe, with plans to initiate a pivotal Phase 3 clinical trial in late 2026, subject to available financing. The Company’s lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial evaluating Gedeptin in combination with an immune checkpoint inhibitor (ICI) as first-line treatment of patients with squamous cell head and neck cancer is planned to initiate during the second half of 2027, subject to available financing.
2. Summary of Significant Accounting Policies
We disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025 those accounting policies that we consider significant in determining our results of operations and financial position. During the nine months ended September 30, 2026, there have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.
Basis of Presentation
The accompanying financial statements include the accounts of GeoVax Labs, Inc. and GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. The financial statements are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding to continue our research and development activities. We believe that our existing cash resources together with access to the credit facility discussed in Note 9 will be sufficient to continue our planned operations into December 2026. We plan to pursue additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note 5 and Note 9.
Recent Accounting Pronouncements
During the nine months ended September 30, 2026, there have been no new accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.
3. Balance Sheet Components
Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist of the following:
|
September 30, 2026 |
December 31, 2025 |
|||||||
|
Prepaid clinical trial costs |
$ | $ | ||||||
|
Prepaid insurance premiums |
||||||||
|
Prepaid rent |
||||||||
|
Prepaid contract manufacturing costs |
||||||||
|
Other prepaid expenses |
||||||||
|
Total prepaid expenses and other current assets |
$ | $ | ||||||
Property and Equipment – Property and equipment consist of the following:
|
September 30, 2026 |
December 31, 2025 |
|||||||
|
Equipment and furnishings |
$ | $ | ||||||
|
Accumulated depreciation and amortization |
( |
) | ( |
) | ||||
|
Total property and equipment, net |
$ | $ | ||||||
In connection with the termination of our laboratory lease (See Note 4) in September 2026, we sold and donated excess laboratory equipment with an aggregate net book value of $
Other Assets – Other assets consist of the following:
|
September 30, 2026 |
December 31, 2025 |
|||||||
|
Prepaid technology license fees |
$ | $ | ||||||
|
Deposits |
||||||||
|
Total other assets |
$ | $ | ||||||
Accrued Expenses – Accrued expenses consist of the following:
|
September 30, 2026 |
December 31, 2025 |
|||||||
|
Payroll-related liabilities |
$ | $ | ||||||
|
Accrued clinical trial costs |
||||||||
|
Other accrued expenses |
||||||||
|
Total accrued expenses |
$ | $ | ||||||
4. Commitments
Operating Leases. During 2025, we leased combined office and laboratory space in the metropolitan Atlanta, Georgia area under an operating lease agreement which expired on December 31, 2025. In August and September 2025, we entered into new agreements for the lease of separate office and laboratory spaces. Each of these agreements provided access to the respective spaces beginning November 1, 2025 for three-year original terms, with periodic base rent adjustments throughout the terms. During April 2026, the landlord for the facility where our laboratory operations were conducted informed us that the facility would close effective September 30, 2026; we vacated the facility on September 18, 2026 and our lease ended as of that date. As of September 30, 2026, the remaining term of our office lease is
Operating lease right-of-use assets and liabilities on the consolidated balance sheet represent the present value of the remaining lease payments over the remaining lease terms. Payments for additional fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. We use our incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.
Total operating lease expense for the three-month and nine-month periods ended September 30, 2026 was $
|
2026 remaining |
$ |
|||
|
2027 |
||||
|
2028 |
||||
|
Total remaining lease payments |
||||
|
Less: imputed interest |
( |
) | ||
|
Total operating lease liability as of September 30, 2026 |
||||
|
Less: current portion |
( |
) | ||
|
Total operating lease liability, net of current portion |
$ |
License Agreements. We have entered into license agreements for various technologies and patent rights associated with our product development activities. These agreements may contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Due to the uncertainty of the achievement and timing of the contingent events requiring payment under these agreements, the amounts to be paid by us in the future are not determinable.
Other Commitments. In the normal course of business, we enter into various contracts and purchase commitments including those with contract research organizations (“CROs”) for clinical trial services, contract manufacturing organizations (“CMOs”) for production of materials for use in our clinical trials, and other independent contractors or academic institutions for preclinical research activities and other services and products. Most contracts are generally cancellable, with notice, at the Company’s option. Payments due upon cancellation may consist of payments for services provided or expenses incurred to date, or cancellation penalties depending on the time of cancellation.
5. Stockholders’ Equity
Reverse Stock Split
On January 9, 2026, we effected a one-for-twenty-five reverse split of our common stock and on November 11, 2026, we effected a one-for-twenty-four reverse split of our common stock. The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits. The roundup of fractional shares associated with the January 2026 reverse stock split resulted in the issuance of an additional
Common Stock and Warrant Transactions
February 2026 Offering. On February 17, 2026, we closed a registered direct offering resulting in the issuance of
March 2026 Warrant Exercise Inducement. On March 31, 2026, we entered into warrant exercise inducement letters with the holders of certain existing stock purchase warrants (with exercise prices ranging from $
May 2026 Warrant Exercise Inducement. On May 7, 2026, we entered into warrant exercise inducement letters with the holders of certain existing warrants (with exercise prices of $
May 2026 Offering. On May 19, 2026, we closed a private placement offering resulting in the issuance of
Other Common Stock Transactions. During June 2026, we issued
August 2026 Warrant Exercise Inducement. On August 25, 2026, we entered into a warrant exercise inducement letter with the holder of certain existing warrants (with exercise prices ranging from $
Other Warrant Exercises. During March 2026, we issued
ATM Program. During 2024, we established an “At-the-Market” continuous offering program (the “ATM Program”), pursuant to which the Company may offer and sell, from time to time through its sales agent, shares of its common stock. During January 2026 we sold
Stock Incentive Plans
We have stock-based incentive plans (the “Plans”) pursuant to which our Board of Directors may grant stock options and other stock-based awards to our employees, directors and consultants. A total of
|
Number of Shares |
Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Term (yrs) |
Aggregate Intrinsic Value |
|||||||||||||
|
Outstanding at December 31, 2025 |
$ | $ | ||||||||||||||
|
Granted |
||||||||||||||||
|
Exercised |
||||||||||||||||
|
Forfeited or expired |
( |
) | ||||||||||||||
|
Outstanding at September 30, 2026 |
$ | $ | ||||||||||||||
|
Exercisable at September 30, 2026 |
$ | $ | ||||||||||||||
The weighted average grant date fair value of stock options awarded during the nine months ended September 30, 2026, was $
|
Risk-free interest rate |
% | |||
|
Expected term (in years) |
||||
|
Expected volatility |
|
% | ||
|
Dividend yield |
% | |||
Stock Purchase Warrants
The following common stock purchase warrants were outstanding as of September 30, 2026:
|
Issue Date |
Number of Shares |
Exercise Price |
Expiration |
||||||
|
July 2025 |
July 2030 |
||||||||
|
September 2025 |
November 2030 |
||||||||
|
December 2025 |
December 2030 |
||||||||
|
February 2026 |
June 2028 |
||||||||
|
February 2026 |
June 2031 |
||||||||
|
March 2026 |
June 2031 |
||||||||
|
May 2026 |
June 2031 |
||||||||
|
May 2026 |
November 2027 |
||||||||
|
May 2026 |
May 2031 |
||||||||
|
August 2026 |
October 2031 |
||||||||
|
Outstanding at September 30, 2026 |
|||||||||
Abeyance Shares
As noted above, as of September 30, 2026, we are holding
6. Stock-Based Compensation Expense
Stock-based compensation expense related to stock options and restricted stock awards is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the classification of the individual to whom the award is granted.
The following table summarizes total stock-based compensation expense included in operating expenses for the periods presented, inclusive of both stock option expense and expense associated with stock awards to consultants:
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Research and development expense |
$ | $ | $ | $ | ||||||||||||
|
General and administrative expense |
||||||||||||||||
|
Total |
$ | $ | $ | $ | ||||||||||||
As of September 30, 2026, there is approximately $
7. Net Loss Per Share
Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding as of September 30, 2026. The Company’s potentially dilutive securities, which include stock options and stock purchase warrants, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. The securities that could potentially dilute basic earnings per share in the future and that have been excluded from the computation of diluted net loss per share totaled
8. Income Taxes
No provision for income taxes was recorded in either of the nine-month periods ended September 30, 2026 and 2025. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of September 30, 2026.
9. Subsequent Events
Issuance of Common Stock Held in Abeyance
During October 2026, we issued an aggregate of
Revolving Loan Agreement
On October 25, 2026, we entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with the Lender name therein. Under the Revolving Loan Agreement, we may request loans from time to time prior to the first anniversary of the Revolving Loan Agreement (the “Maturity Date”) in an aggregate principal amount outstanding at any one time not to exceed $
Loans under the Revolving Loan Agreement bear interest at a rate of
Reverse Stock Split
On November 11, 2026, we effected a one-for-twenty-four reverse split of our common stock. The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split.
Item 2 Management’s Discussion and Analysis of Financial Condition And Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition. This MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes thereto and other disclosures included in this Quarterly Report on Form 10-Q (this “Quarterly Report”), and our audited financial statements and the accompanying notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2026.
Forward-Looking Statements
Information included in this Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,”, “looks forward to”, “may”, “estimates”, “continues”, “should”, “could”, “target”, “potential”, “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. All statements in this Quarterly Report, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, future governmental grants, projected costs, prospects, plans, intentions, expectations and objectives could be forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. We operate in a highly competitive, highly regulated and rapidly changing environment and our business is constantly evolving. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either the impact of all such risk factors on our business. We assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Quarterly Report.
Overview and Recent Developments
GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms.
Our corporate strategy is to advance, protect, and strategically leverage our proprietary vaccine and immunotherapy platforms to develop differentiated preventive and therapeutic solutions for infectious diseases and solid tumors. We aim to efficiently progress our product candidates through clinical development and pursue regulatory approval and commercialization through internal development and selective external licensing and partnership arrangements. We also work collaboratively with academic, governmental, and industry partners to validate our technologies, support development efforts and enhance the strategic value of our pipeline.
GeoVax’s primary near-term strategic development priority is GEO-MVA, an MVA-based vaccine candidate for mpox and smallpox. GEO-MVA is being advanced on an expedited regulatory pathway in Europe and. is intended to address a documented global supply constraint for orthopoxvirus vaccines. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The advancement of GEO-MVA represents the Company’s most near-term opportunity to achieve regulatory approval and potential commercialization.
Our programs are in various stages of development. Key updates for our lead programs are outlined below:
|
● |
GEO-MVA – mpox/smallpox Vaccine Candidate: |
|
o |
GEO-MVA is a MVA vaccine candidate intended for protection against mpox and smallpox. MVA is the vaccine recommended by both the World Health Organization (WHO) and CDC for these indications and is currently used in the U.S. Strategic National Stockpile. |
|
o |
Following scientific advice from the European Medicines Agency (EMA) in May 2025, we intend to proceed directly to a Phase 3 trial, bypassing traditional Phase 1 and 2 studies, subject to final protocol and regulatory alignment. Subject to available financing, we expect to initiate the Phase 3 study in late 2026. |
|
o |
A cGMP clinical drug substance batch of GEO-MVA has been successfully produced to support clinical development. |
|
● |
Gedeptin® -- Gene-Directed Enzyme Prodrug Therapy (GDEPT): |
|
o |
Gedeptin has successfully completed a Phase 1/2 clinical trial (NCT03754933) in patients with advanced HNSCC. This trial was funded in part by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. |
|
o |
Planning activities are underway for a Phase 2 trial to evaluate the addition of intra-tumoral Gedeptin and intravenous fludarabine to recently approved neoadjuvant pembrolizumab as first-line treatment of patients with head and neck squamous cell carcinoma eligible for curative surgery. Subject to available financing, trial initiation is targeted for initiation in the second half of 2027. |
|
● |
Manufacturing Platform – Continuous Avian Cell Line: |
|
o |
GeoVax is developing a continuous avian cell line manufacturing platform for production of its MVA-based vaccines. This platform will enable scalable, high-yield production of vaccine candidates under current cGMP conditions. Thus far, initial process development steps in support of cGMP production of GEO-MVA in the continuous avian cell line have been achieved Unlike traditional egg-based production methods, continuous cell line manufacturing offers greater efficiency, reproducibility and flexibility, supporting rapid response capabilities for emerging infectious diseases and biothreats. This approach is aligned with U.S. and international priorities for modernizing vaccine manufacturing and ensuring supply chain resilience. |
On May 26, 2026, the Company announced a strategic reprioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin®, reflecting increasing clinical, regulatory, and market alignment across these programs. As part of this decision, the Company elected to discontinue active development activities related to its GEO-CM04S1 COVID-19 vaccine candidate. This decision was not related to any safety concerns with the vaccine but reflects the continued evolution and contraction of the global COVID-19 vaccine market, and GeoVax’s focus on programs with clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential.
Financial Overview
Revenue
Our revenues to date have been related to government grants and contracts and other collaborative arrangements in support of our product development activities. We have not generated any revenue to date from the sale of the products we are developing. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization.
Research and development expenses
Since our inception, we have focused and we continue to focus significant resources on our research and development activities, including developing our vector platform and analytical testing methods, conducting preclinical studies, developing manufacturing processes, and conducting clinical trials. Research and development costs are expensed as incurred and consist primarily of the following:
• personnel costs in our research and development functions, including salaries, benefits and stock-based compensation;
• expenses incurred under agreements with CROs, for the conduct of clinical trials;
• expenses incurred under agreements with contract manufacturing organizations (CMOs) that manufacture product used in clinical trials;
• expenses incurred in procuring materials and for analytical and release testing services required to produce vaccine candidates used in clinical trials;
• process development expenses to improve the efficiency and yield of the bulk vaccine;
• laboratory supplies, vendor expenses and other third-party contract expenses related to preclinical research activities;
• technology license fees;
• consultant expenses for services supporting our clinical, regulatory and manufacturing activities; and
• facilities, depreciation and other general overhead expenses.
We expect our research and development expenditures to increase as we advance our existing and future product candidates into and through clinical trials and pursue regulatory approval, especially with regard to the planned GEO-MVA and Gedeptin clinical programs. We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with biotechnology research and development. Due to these uncertainties, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. As we obtain data from preclinical studies and clinical trials, we may elect to discontinue or delay certain development programs to focus our resources on more promising product candidates. Completion of preclinical studies and human clinical trials may take several years or more, but the length of time can vary substantially depending upon several factors. The duration and the cost of future clinical trials may vary significantly over the life of the project because of differences arising during development of the human clinical trial protocols, including the length of time required to enroll suitable patient subjects, the number of patients that ultimately participate in the clinical trial, the duration of patient follow-up, and the number of clinical sites included in the clinical trials.
General and administrative expenses
Our general and administrative expenses consist primarily of personnel costs in our executive, finance, business development and other administrative functions, including stock-based compensation. Other general and administrative expenses include consulting fees, professional service fees for accounting and legal services, lease expenses related to our offices, insurance premiums, intellectual property costs incurred in connection with filing and prosecuting patent applications, depreciation and other costs. We expect our general and administrative expenses will increase in the future as we support expanded research and development activities, prepare for potential commercialization of our current and future product candidates, maintain compliance with requirements of Nasdaq and the SEC, and other general corporate activities.
Critical Accounting Policies and Estimates
This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts them as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
For a description of critical accounting policies that require significant judgments and estimates during the preparation of our financial statements, refer to the Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no significant changes to our critical accounting policies from those disclosed in our 2025 Annual Report.
Recent Accounting Pronouncements – Information regarding recent accounting pronouncements is contained in Note 2 to the financial statements included in this Quarterly Report.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations.
Results of Operations
The following table summarizes our results of operations for the three-month and nine-month periods ended September 30, 2026 and 2025:
|
Three Months Ended Sep. 30, |
||||||||||||
|
2026 |
2025 |
Change |
||||||||||
|
Operating expenses: |
||||||||||||
|
Research and development |
2,819,681 | 5,043,504 | (2,223,823 | ) | ||||||||
|
General and administrative |
1,354,788 | 1,329,711 | 25,077 | |||||||||
|
Total operating expenses |
4,174,469 | 6,373,215 | (2,198,746 | ) | ||||||||
|
Loss from operations |
(4,174,469 | ) | (6,373,215 | ) | 2,198,746 | |||||||
|
Interest income |
18,468 | 54,301 | (35,833 | ) | ||||||||
|
Net loss |
$ | (4,156,001 | ) | $ | (6,318,914 | ) | $ | 2,162,913 | ||||
|
Nine Months Ended Sep. 30, |
||||||||||||
|
2026 |
2025 |
Change |
||||||||||
|
Revenue from government contract |
$ | - | $ | 2,489,145 | $ | (2,489,145 | ) | |||||
|
Operating expenses: |
||||||||||||
|
Research and development |
9,833,652 | 15,127,090 | (5,293,438 | ) | ||||||||
|
General and administrative |
4,055,770 | 4,559,346 | (503,576 | ) | ||||||||
|
Total operating expenses |
13,889,422 | 19,686,436 | (5,797,014 | ) | ||||||||
|
Loss from operations |
(13,889,422 | ) | (17,197,291 | ) | 3,307,869 | |||||||
|
Interest income |
44,922 | 150,943 | (106,021 | ) | ||||||||
|
Net loss |
$ | (13,844,500 | ) | $ | (17,046,348 | ) | $ | 3,201,848 | ||||
Revenue from Government Contract
No revenues associated with government contracts were reported during the nine-month period ended September 30, 2026. During the three-month and nine-month periods ended September 30, 2025, we reported $-0- and $2,489,145, respectively, of revenues associated with the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA), to support advancement of GEO-CM04S1 into a Phase 2b study. In April 2025, we were notified that BARDA elected to terminate the contract for convenience, consistent with its terms.
Research and Development Expenses
Our research and development expenses were $2,819,681and $9,833,652 for the three-month and nine-month periods ended September 30, 2026, as compared to $5,043,504 and $15,127,090 for the comparable 2025 periods, representing decreases of 44.1% and 35.0%, respectively. The overall decrease primarily relates to reduced costs associated with termination of the BARDA contract, as well as lower costs for the GEO-CM04S1 clinical trials and manufacturing costs associated with Gedeptin program. These lower costs were partially offset by increased manufacturing costs associated with the GEO-MVA development program. Research and development expenses for the three-month and nine-month periods of 2026 include stock-based compensation expense of $114,135 and $329,983, respectively; as compared to $130,323 and $390,962, respectively, for the comparable 2025 periods.
General and Administrative Expenses
Our general and administrative expenses were $1,354,788 and $4,055,770 for the three-month and nine-month periods ended September 30, 2026, as compared to $1,329,711 and $4,559,346 for the comparable 2025 periods, representing an increase of 1.9% and a decrease of 11.0%, respectively. The overall decrease during 2026 relates primarily to lower investor relations consulting and other programmatic costs, travel costs, and stock-based compensation expense. General and administrative expenses for the three-month and nine-month periods of 2026 include stock-based compensation expense of $107,504 and $274,719, respectively; as compared to $147,223 and $472,068, respectively, for the comparable periods of 2025.
Other Income
Interest income for the three-month and nine-month periods ended September 30, 2026 was $18,468 and $44,922, respectively, as compared to $54,301 and $150,943, respectively, for comparable periods of 2025. The overall decrease during 2026 is attributable to the average cash balances available for investment.
Liquidity and Capital Resources
The following tables summarize our liquidity and capital resources as of September 30, 2026 and December 31, 2025, and our cash flows for the nine-month periods ended September 30, 2026 and 2025:
|
Liquidity and Capital Resources |
September 30, 2026 |
December 31, 2025 |
||||||
|
Cash and cash equivalents |
$ | 2,150,946 | $ | 3,085,741 | ||||
|
Working capital |
978,595 | 3,377,950 | ||||||
|
Nine Months Ended September 30, |
||||||||
|
Cash Flow Data |
2026 |
2025 |
||||||
|
Net cash provided by (used in): |
||||||||
|
Operating activities |
$ | (11,536,528 | ) | $ | (16,512,193 | ) | ||
|
Investing activities |
7,000 | (27,612 | ) | |||||
|
Financing activities |
10,594,733 | 16,041,861 | ||||||
|
Net decrease in cash and cash equivalents |
$ | (934,795 | ) | $ | (497,944 | ) | ||
Operating Activities – Net cash used in operating activities of $11,536,528 for the nine-months ended September 30, 2026, was due to our net loss of $13,844,500, offset by non-cash items such as depreciation and amortization expense and stock-based compensation expense, and by changes in our working capital accounts. Net cash used in operating activities of $16,512,193 for the nine months ended September 30, 2025, was primarily due to our net loss of $17,046,348, offset by non-cash items such as depreciation and amortization expense and stock-based compensation expense, and by changes in our working capital accounts..
Investing Activities – Net cash provided by investing activities was $7,000 for the nine months ended September 30, 2026 and relates to the sale of laboratory equipment. Net cash used in investing activities was $27,612 for the nine months ended September 30, 2025 and relates to purchases of laboratory equipment.
Financing Activities – Net cash provided by financing activities was $10,594,733 and $16,041,861 for the nine-month periods ended September 30, 2026 and 2025, respectively. Net cash provided by financing activities for each period relates to net proceeds from offerings of our common stock and warrants and exercise of previously issued warrants
Funding Requirements and Sources of Capital
To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks incident to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. We have funded our operations to date primarily from sales of our equity securities and from government grants and clinical trial assistance.
During January 2026, we also sold shares of our common stock pursuant to the ATM Program for net proceeds of approximately $71,200.
On February 17, 2026, we closed a registered direct offering of our common stock and warrants. Net proceeds after deducting placement agent fees and other offering expenses were approximately $885,000.
During March 2026, holders of our previously issued stock purchase warrants exercised their warrants, resulting in cash proceeds to us of approximately $4,800.
On March 31, 2026, we entered into warrant exercise inducement letters with the holders of certain existing warrants whereby the holders agreed to exercise warrants at a reduced exercise price. Net proceeds to us after deducting placement agent commissions and other offering expenses were approximately $762,700.
On May 7, 2026, we entered into warrant exercise inducement letters with the holders of certain existing stock purchase warrants, whereby the holders agreed to exercise their warrants. Aggregate net proceeds to us after deducting placement agent commissions and other offering expenses were approximately $844,100.
On May 19, 2026, we closed a private placement offering of our common stock and warrants. Net proceeds after deducting placement agent fees and other offering expenses were approximately $2,709,800.
During May 2026, holders of our previously issued stock purchase warrants exercised their warrants, resulting in cash proceeds to us of approximately $1,975,700.
On August 25, 2026, we entered into a warrant exercise inducement letter with the holder of certain existing stock purchase warrants, whereby the holder agreed to exercise their warrants. Aggregate net proceeds to us after deducting placement agent commissions and other offering expenses were approximately $3,341,200.
On October 25, 2026, we entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with the Lender name therein. Under the Revolving Loan Agreement, we may request loans from time to time prior to the first anniversary of the Revolving Loan Agreement (the “Maturity Date”) in an aggregate principal amount outstanding at any one time not to exceed $1,000,000.
As of the date of this Quarterly Report, we believe that our existing cash and cash equivalents, together with access to the credit facility discussed in Note 9 are sufficient to fund our operations into December 2026. We plan to pursue additional cash resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources.
There can be no assurance that necessary funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern.
We will need to continue to raise additional capital to support our future operating activities, including progression of our development programs, preparation for commercialization, and other operating costs. We may fund a significant portion of our ongoing operations through partnering and collaboration agreements which, while reducing our risks and extending our cash runway, would also reduce our share of eventual revenues, if any, from our vaccine candidates. Additionally, we may be able to fund certain activities with assistance from government programs.
The sale of additional equity would result in additional dilution to our stockholders. We may also fund our operations through debt financing, which would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market vaccine candidates that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects.
Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and is based on assumptions that may prove to be wrong; actual results could vary materially. Our projection takes into consideration contractual commitments we have made, and expect to make, in the normal course of operating our business, which include (i) obligations to our employees, (ii) our lease obligations, (iii) payments due under license agreements for various technologies and patent rights associated with our product development activities, (iv) arrangements with CROs, CMOs, and other third-party vendors for clinical trials services and production of materials for use in our clinical trials, and (v) other various firm purchase commitments and contractual obligations related to production and testing of our product candidates and the general operation of our business.
We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we expect. Our future capital requirements will depend on many factors, which include but are not limited to:
|
● |
the timing and costs of our ongoing and planned clinical trials; |
|
● |
the timing and costs of manufacturing material for use in clinical trials; |
|
● |
the number and scope of our research programs and the speed at which they are advanced; |
|
● |
the progress and success of our preclinical and clinical development activities; |
|
● |
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; |
|
● |
the costs to attract and retain skilled personnel; |
|
● |
the costs to maintain and expand our infrastructure to support our operations, our product development, and planned future commercialization efforts; |
|
● |
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; |
|
● |
the costs associated with any products or technologies that we may in-license or acquire; and |
|
● |
the costs and timing of regulatory approvals. |
Item 3 Quantitative and Qualitative Disclosures About Market Risk
Not applicable to smaller reporting companies.
Item 4 Controls and Procedures
Evaluation of disclosure controls and procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that the information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to management, including the Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.
Our management has carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial and Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15 or 15d-15 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.
Changes in internal control over financial reporting
There were no significant changes in our internal control over financial reporting that occurred during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Controls
Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.
PART II -- OTHER INFORMATION
Item 1 Legal Proceedings
None.
Item 1A Risk Factors
Except as set forth below, information regarding factors that could affect our results of operations, financial condition or liquidity, have not materially changed from those previously disclosed under “Risk Factors” in Item 1A of our most recent Annual Report on Form 10-K. See also “Forward-Looking Statements,” included in Part I - Item 2 of this Quarterly Report on Form 10-Q. As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A concerning any material changes from the risk factors previously disclosed in our most recent Annual Report on Form 10‑K.
On July 7, 2026, the Company received a notice (the “Notice”) from the Listing Qualifications Department of Nasdaq notifying the Company that it no longer complied with the Stockholders’ Equity Requirement, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended March 31, 2026 did not meet the required minimum, and as of the date of the Notice, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations.
On August 27, 2026, the Company received a Staff Determination Letter (the “Letter”) from the Listing Qualifications Department of Nasdaq notifying the Company that the Staff has determined to delist the Company’s Common Stock from Nasdaq. As set forth in the Letter, the closing bid price of the Company’s Common Stock was below the $1.00 per share minimum required for continued listing for the 30 consecutive business days from July 16, 2026 through August 26, 2026. Nasdaq determined that the Company does not comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Because the Company effected a 1-for-25 reverse stock split on January 9, 2026, Nasdaq further determined that the Company is not eligible for the customary 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv), which applies when an issuer has effected a reverse stock split within the prior one-year period.
The Company requested a hearing before the Nasdaq Hearings Panel, which stayed further action, and the hearing was held on October 13, 2026. There can be no assurance that the Hearings Panel will grant the Company’s request for continued listing, that the Company will ultimately regain compliance with all applicable Nasdaq listing requirements.
In addition to the foregoing, on July 22, 2026, the SEC approved a new Nasdaq listing requirement that would require each Nasdaq listed issuer to maintain a minimum market value of listed securities of at least $5 million. Under this new rule, if the value of an issuer’s listed securities, as measured by each applicable trading day’s closing price, continues to be less than $5 million for a period of 30 consecutive trading days, the issuer’s securities would immediately be delisted, with no compliance or cure period. This new rule also precludes an issuer’s ability to seek a stay of delisting during any appeals process. The new rule (as amended by the SEC) allows Nasdaq hearings panels to reverse the delisting determination to situations where there was an error by Nasdaq staff or if the company satisfies all initial listing requirements. When the hearings panel review is of a deficiency related to continued listing requirements, generally the hearings panel has the discretion to grant a cure period not to exceed 180 days from the date of the Staff Delisting Determination for a company to regain compliance, and finding the company has regained compliance with all applicable listing requirements. Our Common Stock currently trades at levels that are near the $5 million aggregate market value threshold under this Nasdaq continued listing rule. As such, our Common Stock could be subject to Nasdaq delisting proceedings based on the new rule.
If our Common Stock is delisted, we may seek to have our Common Stock quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly less investor interest in, our Common Stock, which may lead to lower trading prices for our Common Stock.
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds
There were no sales of unregistered equity securities during the period covered by this report that have not previously been reported on Form 8-K.
Item 3 Defaults Upon Senior Securities
None.
Item 4 Mine Safety Disclosures
Not applicable.
Item 5 Other Information
During the period covered by this report,
During the period covered by this report, there was no information required to be disclosed by us in a Current Report on Form 8-K that was not so reported, nor were there any material changes to the procedures by which our security holders may recommend nominees to our board of directors.
Item 6 Exhibits
|
Exhibit Number |
Description |
| 4.1 | Form of Common Stock Purchase Warrant, dated August 26, 2026 (2) |
| 10.1 | Form of Inducement Letter, dated August 25, 2026 (2) |
| 31.1* | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 31.2* | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 32.1* | Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2* | Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document (1) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document (1) |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (1) |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (1) |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (1) |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document (1) |
| 104 | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q and included in the Exhibit 101 Inline XBRL Document Set (1) |
_____________________
* Filed herewith
** Indicates a management contract or compensatory plan or arrangement
|
(1) |
These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections. |
|
|
(2) |
Incorporated by reference from the registrant’s Current Report on Form 8-K filed August 28, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.
| GEOVAX LABS, INC. | |||
| (Registrant) | |||
|
|
|
|
|
|
|
|
|
|
|
Date: November 12, 2026 |
By: |
/s/ Mark W. Reynolds |
|
|
|
|
Mark W. Reynolds |
|
|
|
|
Chief Financial Officer |
|
| (duly authorized officer and principal | |||
| financial officer) |